Combination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)
Prospective Observational Trial to Evaluate the Efficacy of the Combination of Osimertinib and Aspirin in Patients With Disease Progression to 3st Generation Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor（EGFR-TKI） Osimertinib
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
This observational or N/A phase trial investigates EGFR T790M and Non-Small Cell Lung Cancer Stage IIIB and is currently ongoing. Daping Hospital and the Research Institute of Surgery of the Third Military Medical University leads this study, which shows 7 recorded versions since 2020 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Feb 2023 — Jul 2024 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Jan 2021 — Feb 2023 [monthly]
Not Yet Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting
▶ Show 2 earlier versions
-
Jan 2020 — Aug 2020 [monthly]
Not Yet Recruiting
Phase: PHASE2 → None
-
Jun 2018 — Jan 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.